biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 79
- Drugs
- 28
- Patents
- 111
NBI-6024
Phase 1 · small molecule · Type 1 Diabetes Mellitus
NBI-6024 for Type 1 Diabetes Mellitus is a Phase 1 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Internal code NBI 6024-0101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NEUROCRINE BIOSCIENCES INC
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Type 1 Diabetes Mellitus
- Status
- completed
- Trials
- 1